Follow us on Twitter
twitter icon@FreshPatents


Restenosis patents

      

This page is updated frequently with new Restenosis-related patent applications.




 Trka kinase inhibitors, compositions and methods thereof patent thumbnailTrka kinase inhibitors, compositions and methods thereof
The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula (i) which are tropomyosin-related kinase (trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (ngf) receptor trka.. .
Merck Sharp & Dohme Corp.


 Devices for controlling magnetic nanoparticles to treat fluid obstructions patent thumbnailDevices for controlling magnetic nanoparticles to treat fluid obstructions
A system for the physical manipulation of free magnetic rotors in a circulatory system using a remotely placed magnetic field-generating stator is provided. In one embodiment, the invention relates to the control of magnetic particles in a fluid medium using permanent magnet-based or electromagnetic field-generating stator sources.
Pulse Therapeutics, Inc.


 Methods and  stenting comprising enhanced embolic protection coupled with improved protections against restenosis and thrombus formation patent thumbnailMethods and stenting comprising enhanced embolic protection coupled with improved protections against restenosis and thrombus formation
Apparatus and methods for stenting are provided comprising a stent attached to a porous biocompatible material that is permeable to endothelial cell ingrowth, but impermeable to release of emboli of predetermined size. Preferred stent designs are provided, as well as preferred manufacturing techniques.
Abbott Laboratories Vascular Enterprises Limited


 Gene delivery stent using titanium oxide thin film coating and  fabricating the same patent thumbnailGene delivery stent using titanium oxide thin film coating and fabricating the same
The present invention relates to a gene delivery stent using titanium oxide thin film coating and a method for fabricating the gene delivery stent. The gene delivery stent according to the present invention may be loaded with a drug having anti-inflammatory and anti-thrombotic effects and simultaneously deliver a gene capable of inhibiting proliferation of vascular smooth muscle cells.
Chonnam National University Hospital


 Substituted pyridazines as prostacyclin receptor modulators patent thumbnailSubstituted pyridazines as prostacyclin receptor modulators
Cyclohexane derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..
Arena Pharmaceuticals, Inc.


 Variants of c-type natriuretic peptide patent thumbnailVariants of c-type natriuretic peptide
The present disclosure provides variants of c-type natriuretic peptide (cnp), pharmaceutical compositions comprising cnp variants, and methods of making cnp variants. The cnp variants are useful as therapeutic agents for the treatment of diseases responsive to cnp, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis)..
Biomarin Pharmaceutical Inc.


 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors patent thumbnail3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
(wherein r1, r2, r3, r4, r5, r6, r7, x, y and z are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as modulators of the ccr2 and/or ccr5 receptor.

 Selective inhibitors of c-fos and their antiproliferative properties patent thumbnailSelective inhibitors of c-fos and their antiproliferative properties
Selective inhibitor of c-fos and their antiproliferative properties the invention relates to selective inhibitor of c-fos for use in the prevention and/or treatment of cancers and restenosis.. .
Centre National De La Recherche Scientifique(cnrs)


 5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative patent thumbnail5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative
A compound represented by the general formula (i) or a pharmacologically acceptable salt thereof has an excellent lcat-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-hdl-cholesterolemia, hyper-ldl-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein r is an optionally substituted aryl group or an optionally substituted heteroaryl group, and r1 is a hydrogen atom or a hydroxy group.. .
Daiichi Sankyo Company, Limited


 Drug-eluting coatings on poly(dl-lactide)-based scaffolds patent thumbnailDrug-eluting coatings on poly(dl-lactide)-based scaffolds
Stents including a poly(d,l-lactide)(pdlla)-based scaffold and pdlla based therapeutic layer are disclosed. The pdlla based scaffold may be amorphous and may include a primer layer.
Abbott Cardiovascular Systems Inc.


Activators of cxcr3 for the treatment of angiopathies of the eye

The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of c-x-c chemokine receptor 3 (cxcr3). In some embodiments, the activator of cxcr3 is interferon-γ-inducible 10 kda protein (ip-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the c-terminal α-helix of ip-10.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education

Hybrid stent and making

A stent is formed by encasing or encapsulating metallic rings in an inner polymeric layer and an outer polymeric layer. At least one polymer link connects adjacent metallic rings.
Abbott Cardiovascular Systems Inc.

Compositions and methods for treating and preventing neointimal stenosis

Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a tgfβ inhibitor, a smad2 inhibitor, an fgf receptor agonist, a let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (endo-mt) of vascular endothelial cells into smooth muscle cells (smc) at sites of endothelial damage.
Yale University

Uses of kappa opioid synthetic peptide amides

The invention relates to methods of use of synthetic peptide amides that are ligands of the kappa opioid receptor in the treatment and prevention of kappa opioid receptor-associated diseases and conditions; and particularly to uses of these agonists in the prophylaxis, inhibition and treatment of pain, inflammation and pruritis associated with a variety of diseases, disorders and conditions. Inflammatory conditions preventable or treatable by the methods of the invention include diseases and conditions associated with elevated levels of a proinflammatory cytokines, such as tnf-α, il-1β, il-6, mmp-1 and mmp-3.
Cara Therapeutics, Inc.

Cell-free tissued engineered vascular grafts

A composition containing a macrophage inhibitor may be administered in an effective amount to prevent, inhibit or reduce restenosis, thrombus or aneurysm formation in implanted polymeric vascular grafts. The composition may be administered prior to vascular graft implantation, at the same time as vascular graft implantation, following vascular graft implantation, or any combination thereof.
Yale University

Wnt/beta-catenin inhibitor-eluting endovascular stent

A product comprising a stent for a human blood vessel which comprises (i) a scaffold which is impregnated with, adsorbed with, or coated with an inhibitor of a wnt/p-catenin pathway, or (ii) a scaffold coated with a polymer, which polymer is impregnated with, adsorbed with, or coated with an inhibitor of a wnt/p-catenin pathway, and methods of use to reduce the risk of restenosis.. .
Albert Einstein College Of Medicine, Inc.

Method of producing personalized biomimetic drug-eluting coronary stents by 3d-printing

A method for using 3d printing technology produces personalized biomimetic drug-eluting coronary stent and the product thereof. The process of manufacturing stent, based on coronary angiography imaging data, measures the diameter of diseased coronary and conducts 3d reconstruction.

Variants of c-type natriuretic peptide

The present disclosure provides variants of c-type natriuretic peptide (cnp), pharmaceutical compositions comprising cnp variants, and methods of making cnp variants. The cnp variants are useful as therapeutic agents for the treatment of diseases responsive to cnp, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis)..
Biomarin Pharmaceutical Inc.

Methods for treating restenosis using annexin a5

A method for the prophylaxis or treatment of restenosis comprising administering a therapeutically effective amount of annexin a5 or a functional analogue or variant thereof to a patient in need of such treatment. A method for the treatment of stenosis in a patient comprising performing an intervention for the treatment of stenosis in conjunction with administering a therapeutically effective amount of annexin a5 or a functional analogue or variant thereof.
Annexin Pharmaceuticals Ab

Inhibition of sgk1 in the treatment of heart conditions

The present invention relates to the treatment of acquired and genetic heart conditions in a subject by the inhibition of sgk1, including long qt syndrome and cardiovascular disease, including dilated cardiomyopathy. Cardiovascular diseases treatable by sgk1 inhibition include heart failure, arrhythmia, ischemic injury, ischemic infarction, cardiac fibrosis, vascular proliferation, restenosis, dilated cardiomyopathy, and stent failure.
Beth Israel Deaconess Medical Center, Inc.

Novel peptide compound for inhibiting restenosis and promoting re-endothelialization and preparing the same

Provided are a peptide compound prepared by additional synthesis in a drug having an effect of inhibiting restenosis, a composition for inhibiting restenosis and promoting re-endothelialization including the peptide compound, and a stent having a surface coated by using the composition, in order to overcome a restenosis problem in the stent.. .
Chonnam National University Hospital

Novel peptide compound for inhibiting restenosis and promoting re-endothelialization and preparing the same

Provided are a peptide compound prepared by additional synthesis in a drug having an effect of inhibiting restenosis, a composition for inhibiting restenosis and promoting re-endothelialization including the peptide compound, and a stent having a surface coated by using the composition, in order to overcome a restenosis problem in the stent.. .
Chonnam National University Hospital

Trka kinase inhibitors, compositions and methods thereof

The present invention is directed to benzyl urea compounds of formula (i) which are tropomyosin-related kinase (trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (ngf) receptor trk-a, trk-b and/or trk-c.. .
Merck Sharp & Dohme Corp.

Trka kinase inhibitors, compositions and methods thereof

The present invention is directed to benzyl urea compounds of formula (i) which are tropomyosin-related kinase (trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (ngf) receptor trk-a, trk-b and/or trk-c.. .
Merck Sharp & Dohme Corp.

Novel peptide compound for inhibiting restenosis and promoting re-endothelialization and preparing the same

Provided are a peptide compound prepared by additional synthesis in a drug having an effect of inhibiting restenosis, a composition for inhibiting restenosis and promoting re-endothelialization including the peptide compound, and a stent having a surface coated by using the composition, in order to overcome a restenosis problem in the stent.. .
Chonnam National University Hospital

Methods for treating cancer with trka receptor tyrosine kinase antagonists

The disclosure further concerns the use of such compounds in the treatment and/or prevention of certain types of cancers, pain, inflammation, restenosis, atherosclerosis, psoriasis, thrombosis, alzheimer's, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination.. .

Progesterone-containing compositions and devices

Progesterone-containing compositions and devices that can maintain opening of a body passageway are described. One aspect of the invention provides a therapeutically effective (e.g., relaxative, anti-oxidative, anti-restenotic, anti-angiogenic, anti-neoplastic, anti-cancerous, anti-precancerous and/or anti-thrombotic) composition or formulation containing progesterone and optionally vitamin e and/or conjugated linoleic acid.

Synthetic apelin fatty acid conjugates with improved half-life

Wherein said fatty acid is covalently linked to the n-terminus of the peptide via one of its carboxylic acid functionality, optionally via a polyethylene glycol linker; and wherein the two cysteine amino acids labeled with “*” form a disulfide bond between the thiol functionalities of their side chain. The conjugates are agonist of the apj receptor.

Location tracking of a metallic object in a living body

A method and apparatus are provided for determining and tracking location of a metallic object in a living body, and then directing a second modality such as ultrasound waves to the determined location. The metal detector may be a radar detector adapted to operate on a living body.
Kyma Medical Technologies Ltd.

Adhesive composition for carrying therapeutic agents as delivery vehicle on coating applied to vascular grafts

Water-soluble polymeric adhesive compositions and their use as delivery vehicles for carrying therapeutic agents on implantable devices, such as vascular grafts, are disclosed. Use of drug-coated vascular grafts is demonstrated for delivery of the therapeutic agents in vivo, thereby inhibiting restenosis or neointimal hyperplasia of the vascular graft and inhibiting infection at the vascular graft site.
The University Of Tennessee Research Foundation

Perivascular delivery system and method

A perivascular delivery system and method are provided for preventing the development of restenosis of a blood vessel. The perivascular delivery system includes a sheath having inner face engageable with an outer surface of the blood vessel and first and second ends.
Wisconsin Alumni Research Foundation

Electrically-induced fluid filled balloon catheter

The present disclosure relates generally to the use of medical devices for the treatment of vascular conditions. In particular, the present disclosure provides devices and methods for using electrically-induced pressure waves to disrupt vascular blockages.

Plasma modified medical devices and methods

Coatings, devices and methods are provided, wherein the contacting surface of a medical device with at least one contacting surface for contacting a bodily fluid or tissue, wherein long-lasting and durable bioactive agents or functional groups are deposited on the contacting surface through a unique two-step plasma coating process with deposition of a thin layer of plasma coating using a silicon-containing monomer in the first step and plasma surface modification using a mixture of nitrogen-containing molecules and oxygen-containing molecules in the second step. The two-step plasma coating process enables the implantable medical device to prevent both restenosis and thrombosis under clinical conditions.

Progenitor endothelial cell capturing with a drug eluting implantable medical device

A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is provided with a coating with a pharmaceutical composition containing a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues.

Laser-induced fluid filled balloon catheter

The present disclosure relates generally to the use of medical devices for the treatment of vascular conditions. In particular, the present disclosure provides devices and methods for using laser-induced pressure waves to disrupt vascular blockages.

Bioconjugates of synthetic apelin polypeptides

Or an amide, an ester or a salt thereof, wherein x1, x2, x3, x4, x5, x6, x7, x8, x9, x10, x11, x12 and x13 are defined herein and a half-life extending moiety wherein the peptide and the half-life extending moiety are covalently linked or fuse, optionally via a linker. The polypeptides are agonist of the apj receptor.

Devices, systems, and methods for in-stent restenosis prediction

Intravascular devices, systems, and methods are disclosed. In some instances, a method for treating a vessel of a patient includes collecting intravascular ultrasound imaging data of the placement of the stent using the intravascular ultrasound imaging device, estimating, using a processing device, a restenosis probability value based on the intravascular ultrasound imaging data of the placement of the stent and communicating the estimated restenosis probability value to a clinician.
Volcano Corporation

Cyclic apelin derivatives for the treatment of heart failure

The invention provides a synthetic polypeptide of formula i′: x1-r-x3-r-l-x6-x7-k-x9-p-x11-x12-x13 or an amide, an ester, a salt thereof, or a bioconjugate thereof, wherein x1, x3, x6, x7, x9, x11, x12 and x13 are defined herein. The polypeptides and bioconjugates are agonist of the apj receptor.
Novartis Ag

Disulfide cyclic polypeptides for the treatment of heart failure

The invention provides a synthetic polypeptide of formula i′: x1-r-p-r-x5-x6-x7-k-x9-p-x11-x12-x13 or an amide, an ester, a salt or a bioconjugate thereof, wherein x1, x5, x6, x7, x9 and x11 to x13 are defined herein. The polypeptides and bioconjugates are agonist of the apj receptor.
Novartis Ag

Progenitor endothelial cell capturing with a drug eluting implantable medical device

A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is coated with a pharmaceutical composition consisting of a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues.
Orbusneich Medical, Inc.

Cyclic polypeptides for the treatment of heart failure

Or an amide, an ester or a salt thereof, or a bioconjugate thereof, wherein x1, x3, x4, x7, x8, x9, x10, x11, x12 and x13 are defined herein. The polypeptides are agonist of the apj receptor.

Treatment for diseases relying on discovery that thioredoxin mediates nitric oxide release in cells

Patients having a disease associated with high level of thioredoxin system activity or a requirement for nitric oxide, e.g. Large cell lymphoma or restenosis, are treated with a thioredoxin reductase inhibitor, e.g.

Bet inhibition therapy for heart disease

Method for treating cardiac diseases using bet inhibitors including jq1 are provided. Methods for treating cardiac hypertrophy, method for treating heart failure not arising from inflammation, methods for treating myocardial infarction, methods for cardioprotection and methods for inhibiting restenosis are described herein.
The Brigham And Women's Hospital, Inc.

Electrodeposition coating for medical devices

The present disclosure relates generally to coating medical devices. In particular, the present disclosure provides materials and methods for coating a portion of a balloon catheter with a pharmaceutical agent using electrodeposition techniques.
The Spectranetics Corporation

Progenitor endothelial cell capturing with a drug eluting implantable medical device

A medical device for implantation into vessels or luminal structures within the body is provided. The medical device, such as a stent and a synthetic graft, is coated with a pharmaceutical composition consisting of a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues.
Orbusneich Medical, Inc.

The detection of restenosis risk in patients receiving a stent

Provided is a method of selecting a stent for implantation in the circulatory system of a human being. The method comprises obtaining a blood sample from a patient who requires implantation of a stent and testing said blood sample to determine a platelet coagulability level.

Assessment of cardiac health and thrombotic risk in a patient

The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and/or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value.

Compositions and methods for reducing neointima formation

Compositions, devices, grafts and methods for reducing or preventing anti-neointima following cardiovascular injuries and interventions are disclosed. The compositions, devices, and grafts typically include an effective amount of a ctp synthase 1 inhibitor to reduce proliferation of vascular smooth muscle cells, without substantial reducing the proliferation of endothelial cells.
University Of George Research Foundation, Inc.

Catheter balloon provided with microboreholes and a metal mesh

The present invention relates to a balloon catheter having a catheter balloon with micro drillings and a metal mesh and particularly to balloon catheters for the cardiac field for minimizing or preventing restenosis. Active agent solutions may be administered through the micro drillings such as using an injection catheter..
Ippyramids Gmbh

Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device

Drug-delivery systems such as drug-delivery stents having an anti-proliferative agent such as everolimus and an anti-flammatory agent such as clobetasol are provided. Also disclosed are methods of treating a vascular impairment such as restenosis or vulnerable plaque..
Abbott Cardiovascular Systems Inc.

Pharmaceutical formulation for use in the treatment and/or prevention of restenosis

The present invention relates generally to a pharmaceutical formulation for use in the treatment and/or prevention of restenosis in a subject in need thereof. Methods of treatment and/or prevention are also provided..
Centre Hospitalier Universitaire Vaudois (c.h.u.v.)



Restenosis topics:
  • Restenosis
  • Atherosclerosis
  • Endothelial
  • Blood Vessel
  • Proliferation
  • Angiogenesis
  • Hypertension
  • Inflammation
  • Hyperplasia
  • Smooth Muscle
  • Thrombosis
  • Dysfunction
  • Myocardial Infarction
  • Endothelial Dysfunction
  • Infarction


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Restenosis for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Restenosis with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.3371

    file did exist - 2343

    0 - 1 - 51